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Complications of Injectable Soft Tissue Filler
INTRODUCTION
Soft tissue fillers for soft tissue augmentation and the correction of 
wrinkles have been used widely in recent years. Various kinds of 
products have been developing and the demand for these products 
is growing more and more rapidly. The popularity of soft tissue fill-
ers was based on the safety profile, easy application and low compli-
cations rate [1]. As the use of fillers increases, many complications 
have arisen recently. The range of complications varies widely. Local 
and temporary reaction to the filler is common and self-limited. 
Ozturk et al. [1] named the minimal and self-limited complication 
simply as adverse sequelae. Misplacement of filler, allergic reaction, 
infection and biofilm formation, and delayed granulomatous reac-
tion can occur and proper treatments are necessary [1-3]. Skin ne-
crosis and visual impairment are not common but it is a disaster to 
both the patient and the clinician [4,5]. These complications have to 
be treated immediately and properly. Clinicians are familiar with 
the nature and property of most commonly used fillers and their 
procedure technique. Enough practice is necessary to prevent vari-
ous complications because injection technique is critical. Although 
clinicians take care of above-mentioned factors, complications can 
develop unexpectedly. Clinicians should be aware of the method to 
deal with the complications. In this article, we introduce the three 
different groups of fillers according to their origin and discuss prop-
erties of each filler and possible complications. We also review how 
to avoid or manage the complications of soft tissue fillers. 
Classification of fillers 
Recently, various kind of soft tissue filler are available. Each filler has 
its own property. So the clinician has to choose proper the filler ac-
cording to the patient’s need to obtain good aesthetic result and to 
prevent undesired complications. In order to understand the nature 
of each filler, filler can be categorized the three broad groups, autol-
ogous, biologic, and synthetic filler, according to origin [6]. First, 
autologous filler can be obtained from own tissue such as dermis, 
fascia, cartilage, and fat [6-8]. Among them, autologous fat is most 
common injectable material. Autologous fat is regarded as ideal 
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material in terms of nontoxicity, noncarcinogenicity, and biocom-
patibility. But a major drawback is its unpredictable absorption rate. 
And donor site morbidity is inevitable to obtain the fat [8]. So au-
tologous fat graft is a good but somewhat inconvenient option com-
pared with commercial products. Second is biologic filler. This is 
made up of biologic materials which are organic source from hu-
man, animal, or bacteria [6]. Biologic fillers have been used widely. 
However they can cause hypersensitivity reaction and immune re-
jection response and the effect lasts temporarily [9]. The commonly 
used biologic fillers are acellular soft-tissue matrix, collagen, and 
hyaluronic acid (HA) [9,10]. Collagen fillers are derived from mate-
rials extracted from bovine, porcine, and human body. Cosmo-
Derm® and CosmoPlast® containing the type 1 collagen derived 
from bioengineered skin [11]. This filler was created based on the 
idea that as type 1 collagen decreases with age, dermis loses its elas-
ticity [11]. It can be used with HA fillers together. The benefit is de-
creased downtime, decreased bruising, decreased pain on injection 
[11]. HA filler is the most commonly used one. HA is a glycosami-
noglycan which is a component of connective tissue such as bone, 
cartilage, skin, and synovial fluid. The typical product of HA filler is 
Restylane® [12,13]. Restylane® is a nonanimal stabilized HA gel and 
was approved by Food and Drug Administration (FDA) in 2003 for 
facial wrinkle correction [6]. It is made from bacteria by biofermen-
taion process and has less hypersensitivity reactions and transmis-
sion of harmful infectious source [14]. Restylane® subdivides into 
Restylane Touch (Fine Lines), Restylane, Perlane according to dif-
ference size of the constituent particle [13]. Third, there is the syn-
thetic filler which is made using silicone, polymethylmethacrylate 
(PMMA), Calcium hydroxyapatite, and Poly-L-lactic acid (PLLA) 
[6]. The effect of synthetic filler continues permanently. Silicone 
had been used for aesthetic purpose in the past, but it has many 
problems. It becomes hardness and migrates. Also silicone causes 
inflammation and skin necrosis. ArteFill® is made from PMMA 
microspheres suspended in bovine collagen. After injection of Ar-
teFill®, bovine collagen is absorbed. PMMA is surrounded by pa-
tient’s own collagen and becomes stable. By this principle, it makes 
that ArteFill® continues permanently [15]. Radiesse® is made from 
a mixture of calcium hydroxyapatite and polysaccharide gel in the 
ratio of three to seven [16]. Sculptra® is made from the PLLA. The 
advantage of Sculptra® is excellent biocompatibility [17,18]. The 
permanent filler remains in the body for a long time, it is more dif-
ficult to manage the complication than reversible filler. 
The complication of soft tissue filler
The local reaction in the filler injection site
Bruise, swelling, redness, tenderness, and pain in the filler injection 
site are the most commonly appearing complications. Narins et al. 
[14] revealed that over 90% of patients treated with HA filler (Re-
stylane®) or bovine collagen (Zyplast®) showed theses symptoms 
and which improved within 7 days or less in his multicenter com-
parative study. Although this local reaction is minor and self-limit-
ed, clinicians have to notify patients of the possibility of local reac-
tion. Especially, the patient who takes anticoagulant drugs requires 
careful attention. The patient who takes aspirin due to cardiac dis-
ease or cerebral infarction has to stop the drugs five or seven days 
before the procedure. Nonsteroidal anti-inflammatory drug (NSA-
ID), vitamin E, and herbal medicine also have to be stopped seven 
or ten days before the procedure because these dietary supplements 
can alter the coagulation [3,19]. So although filler injection is a sim-
ple technique, checking the general condition of patient and the se-
lection of proper patient are important. Also the explanation of mini-
mal complications to patient is important. So if we reduce the local 
reaction, patient satisfaction would be improved. 
Filler placement
Depth of injection determines the filler placement [2]. Filler injec-
tion too superficial or too deep can cause the problems. Generally, 
if fillers are injected into too superficially, surface of injected site 
could be irregular and lumpy. It could become hard and palpable 
on the skin. Therefore fillers should be injected into the appropri-
ate layer according to each kind of filler. 
HA filler 
HA filler should be injected into the deep dermal layer or subder-
mal layer [20]. If HA filler is injected too superficially, it would be 
appear as a visible lump [21]. The color of skin could be bluish in 
the around the injection area. This appearance is known as Tyndall 
effect. Tyndall effect is that different wavelength light is scattered 
differently on the particles it encounters [20,22]. That is, bluer and 
shorter wavelength light is scattered much more than redder and 
longer wavelength light [22]. So too superficial injection of HA filler 
looks bluish and inversely it warns that HA filer was injected into a 
too superficial layer [22]. Massaging the injection site can relieve the 
hardness and lump [22,23]. Hyaluronidase can also be helpful. 
There is no clear standard how to use hyaluronidase. The activity of 
hyaluronidase depends on the kind of HA filler, pH, and biologic 
factor of patient. Bailey et al. [20] used 75 unit hyaluronidase mixed 
with 1% lidocaine 1.5 mL. Brody [23] reported that 15 unit hyaluro-
nidase could relieve the problems within 24–48 hours. DeLorenzi 
[2] reported effective treatment using 15–50 unit hyaluronidase. Skin 
test is needed prior to using hyaluronidase and local wheal and flare 
reaction is positive reaction within 5 minutes after the injection of 3 
units (0.02 mL) intradermally [23].
Calcium hydroxylapatite
Calcium hydroxylapatite should be injected into the deep dermal 
layer and subdermal layer [20]. If calcium hydroxylapatite is inject-
ed into the too superficial layer, it would appear as a white nodular 
finding. And normal muscle movement results in filler migration 
and dislocation especially in the lip. Eventually, this action causes 
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nodule formation superficially [24]. Therefore Radiesse® which is a 
mixture of calcium hydroxyapatite with polysaccharide is not rec-
ommended for injection to the lip [3]. When nodular formation 
occurs after injection of calcium hydroxyapatite, intralesional ste-
roid injection, massage, and direct excision can be treatment [24]. 
PMMA
PMMA is one kind of synthetic filler and permanent filler. It is avail-
able in the United States market as Artefill® and in the Europe as 
Artecoll® [20]. This filler also should be injected to the deep dermal 
layer and subdermal layer [20]. PMMA can cause long lasting pruri-
tus and redness. It is not common, but hypertrophic scar can be de-
veloped [20,25]. Pruritus and redness in local area can be relieved 
through intralesional steroid injection and application of steroid 
ointment on the wound. Intralesional steroid injection and pulsed 
dye laser can be effective to the hypertrophic scar [3,25].
Infection 
The face has good blood supply and metabolic rate, so infection af-
ter filler injection is not common [26]. But basic antiseptic prepa-
ration using chlorhexidine and alcohol for face is important [3]. 
The reason why aseptic preparation and procedure is important is 
that bacterial infection can make biofilm. Once biofilm was made, 
bacteria have a safe room and bacteria grow very slowly, bacterial 
culture test shows usually negative [2]. Foreign body and implants 
contaminated by biofilm can cause chronic infection and repeated 
recurrence because it is difficult for the antibiotics to reach the bac-
teria [2,27]. Chronicity and recurrence of infection is critical con-
sequence of bilfilm [26]. Complete resolution is impossible without 
removal of foreign body or implants with its biofilm [26]. This is 
also related to the delayed-out nodules formation. The common 
viral infection source is herpes simplex virus [2]. So some patients 
who have a history of herpes simplex infection may be given pro-
phylactic antiviral drugs [2]. The patients infected with herpes 
simplex now should not be performed the filler injection [21]. In 
immunocompromised patients, candida infection can occur after 
filler injection [2]. So clinicians have to consider the general condi-
tion of patients as well as their needs. 
Allergic reaction 
All fillers except autologous tissue can cause foreign body reactions 
ranging from simple immune reaction to life-threatening anaphy-
laxis [20]. Skin test is a requisite procedure to prevent hypersensitiv-
ity reaction. The local allergic reaction such as erythema, indura-
tion, burning, and subcutaneous lumps can occur but does not de-
velop long-lasting morbidity [20]. It can be relieved by using topical 
tacrolimus, antihistamine, intralesional steroid injection, and sys-
temic steroid therapy [20]. Hypersensitivity reaction of HA filler is 
not common but sometimes is reported. Angioderma-type hyper-
sensitivity of HA filler infection in the upper lip was reported [28]. 
The injection of lidocaine for nerve block or botulinum neurotoxin 
type A at the same session can result in hypersensitivity [3]. 
 Hypersensitivity reaction cannot be predicted, thus clinicians 
should be well aware of the possibility of the hypersensitivity reac-
tions from the fillers they used.
Nodular reaction 
Nodules due to filler injection can be divided into two categories. 
First is the type developing just after injection. Nodules in this cat-
egory are resulted from the above-mentioned too superficial injec-
tion. Another category is nodule developing a few months later. 
Generally, granulomatous reaction is mainly responsible for these 
delayed nodules. If the infection and inflammation may be devel-
oped after filler injection, delayed hypersensitivity reaction and 
sterile abscess can occur. This process can lead to granulomatous 
reaction and finally result in the inflammatory nodule or delayed 
nodule over time [29]. The main treatment of inflammatory nod-
ule is reducing the inflammation. Local and systemic steroid thera-
py, intralesional steroid injection, antibiotics, hyaluronidase, 5-flu-
orouracil, allopurinol, surgical excision can be used [29]. 
 Bovine collagen has high risk for hypersensitivity reaction. Heise 
et al. [30] reported that the patients who were negative in skin test 
showed temporary granulomatous inflammation from the delayed 
hypersensitivity reaction. And he recommended that bovine colla-
gen injection should be performed at least four weeks after skin test 
[30]. In the case of HA fillers, most nodules are due to a too superfi-
cial injection because HA is absorbed and does not remain in the 
body for a long time. It is not common but delayed hypersensitivity 
reaction can result in granulomatous foreign body reaction and ster-
ile abscess [31,32]. Macrophage and lymphocyte infiltration and 
foreign-body giant cell can be identified in the nodule by histologic 
stain. Management includes antibiotics, hyaluronidase, intralesional 
or systemic steroid therapy, and surgical excision [2,31]. PLLA is 
synthetic filler approved by the FDA as the filling material for the fa-
cial lipoatrophy in patient infected with human immunodeficiency 
virus (HIV) [33]. Delayed inflammatory nodule is most common in 
PLLA except the silicone. Valantin et al. [33] reported that among 
fifty patients, twenty-two patients developed the delayed inflamma-
tory nodule. Those were palpable but non-visible micronodules and 
developed from six months to sixty months after injection [33]. Sur-
gical excision is preferable choice of management and other medical 
treatments are not effective [29]. Calcium hydroxyapatite is a syn-
thetic filler and it has low immune response. Deep dermal and sub-
dermal layer are the proper layers of injection. The injection around 
lip should be avoided to prevent nodular formation [31,34]. Delayed 
nodule due to calcium hydroxyapatite usually occurs in twelve 
weeks. It appears as a subcutaneous white or yellow nodule. Intrale-
sional steroid injection, fractional CO2 laser, and surgical excision 
would be effective treatment [29,35]. PMMA is difficult to resolve 
the misplacement of filler because it is permanent filler. Deep der-
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mal and subdermal layer are the proper layers for injection [20]. If 
filler injected to superficial layer, massage in the injection site can be 
resolve and minimal movement of lip can be help to prevent the 
nodular formation [15]. PMMA can also cause the delayed granu-
lomatous reaction and make late-onset nodule. Intralesional steroid 
is effective and surgical excision can be possible [15,36]. Polyacryl-
amide has high biocompatibility and foreign body reaction is not 
common. However it can act as a good bed for normal flora in the 
skin and mucosa. This phenomenon makes the biofilm and causes 
chronic inflammation [37,38]. Chronic inflammatory nodule can 
occur from a few days to a few months, it usually accompanies ery-
thema and pain [39,40]. This infectious nodule with biofilm has 
been distinguished from other delayed nodule, because steroid 
therapy can worsen symptoms through the formation of biofilm. 
Therefore aseptic procedure is especially important for injection of 
polyacrylamide [41]. 
Skin necrosis 
One of the serious complications is skin necrosis. It results when the 
injected filler flows into the vessel directly and compresses the vessel 
to impede the blood supply [3,20]. Various fillers can cause skin ne-
crosis. HA filler to improve the glabellar wrinkles caused arterial 
embolization, and calcium hydroxylapatite filler to augmentation of 
nose caused ocular ischemia and paralysis, and Juvederm Ultra 
Plus® for augmentation rhinoplasty caused oculomotor nerve palsy, 
and skin necrosis in the nose, glabella, and forehead [5,42,43]. The 
glabellar area is risk area because it has blood supply by the terminal 
branch of nasal dorsal artery [20]. Ozturk et al. [1] reported that 
skin necrosis occurred most frequently when filler was injected to 
the nose. If the filler flows into the vessel, pain immediately occurs. 
Subsequently blanching, duskiness, and ecchymosis follow. Pain, 
skin discoloration, swelling, bruise, and erythema continue in one 
or two days. Soft tissue defect, ulceration, and eschar occur in three 
or seven days. Ozturk et al. [1] reported that skin necrosis in direct 
filler injection site was 46.2% and skin necrosis in the area which 
has blood supply from impaired vessel was 28.2%. When presymp-
tom for skin necrosis occur after filler injection, immediate treat-
ment should start for increasing the circulation. Covering warm 
gauze, tapping the area, applying nitroglycerin, and prostaglandin 
administration could be performed [3,20]. Also local or systemic 
antibiotics, local or systemic steroid, low-molecular-weight heparin, 
and local hyperbaric treatment could be effective [1,20]. Once skin 
necrosis has occurred, intensive wound care and meticulous surgi-
cal debridement of necrotic tissue is required [1,5]. Preventing sec-
ondary infection and accelerating reepithelization are also required 
[1]. Epidermal growth factor and sodium hyaluronate gel can be 
tried [5]. In another report, two patients who developed the nasal 
skin necrosis after HA filler injection were treated successfully with 
autologous adipose derive stem cell [44]. It is not clear the effect of 
hyaluronidase for skin necrosis due to HA filler. Kim et al. [45] per-
formed the animal experiment to evaluate the role of hyaluronidase. 
They injected hyaluronidase subcutaneously to the ear which had 
auricular arteries injury by HA filler. The subcutaneous injection of 
hyaluronidase within 4 hours could minimize the skin necrosis [45].
Visual impairment 
Visual impairment is the worst complication after filler injection. It 
develops because the filler flows reversely from the peripheral vessel 
to ophthalmic artery. And this occurs the ophthalmic artery embo-
lism [42,46,47]. This complication can be developed from any kind 
of filler such as HA, PMMA, collagen, injectable dermal matrix, and 
PLLA. Glabellar area is most risk area, and nose and forehead are 
also at risk. So clinicians have to pay attention to injections in this 
area. Visual impairment occurs within the few minutes after injec-
tion. It always develops with pain in the involved eye. Other symp-
toms are sweating, nausea, vomiting, headache, paralysis of oculo-
motor muscle and ptosis [42]. There are subjective symptoms such 
as headache, toothache, and pain in the involved eye. Clinicians 
should keep in mind of these symptoms during procedure [42,47]. 
If patient complains these complications, the filler injection has to 
stop immediately [47]. The procedure for vasodilatation, gently 
massage and application of warm gauze and nitroglycerine paste, is 
necessary [48]. Serious visual impairment and skin necrosis are ad-
verse effect on both the patient and the clinician. So clinicians need 
the sufficient education on filler and technical practice. 
 There are common precautions and tips for prevent the serious 
complication such as skin necrosis and visual impairment. Basic 
techniques are aspiration before injection, injection with needle 
withdrawal, slow injection of small amount, using the blunt-tipped 
microcannula, and pinching and tenting of skin [1,4,20,48,49]. In the 
glabellar area, the needle tip should be placed the superficially and 
medially to avoid the injury of supratrochlear vessels [20,48].  
CONCLUSION
Soft tissue fillers have been used widely in these days and the de-
mand for filler is expected to increase more and more. Various 
kinds of filler are developed and commercialized. Soft tissue filler 
is a simple and easy method to achieving the satisfying aesthetic 
result compared with other methods. But indiscreet use of filler 
can cause many complications. To reduce the complications, clini-
cians should know the properties and possible complications of the 
commonly used fillers. Sufficient education and practice of injec-
tion techniques is important. 
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